Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30561555 | 1.00 | ATM (0.48) | ATMMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL8660338 | 1.00 | ATM (0.48) | ATMMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL16001322 | 0.82 | ATM (0.47) | ATMMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL22901480 | 0.82 | ATM (0.47) | ATMMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL11628193 | 0.77 | ATM (0.43) | ATMMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL813719 | 0.77 | HTR1A (0.47) | ATMMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL14223522 | 0.77 | ALDH1A1 (0.43) | ATMMEN1KMT2AALDH1A1TSHR | |
| Iodide SCHEMBL11744749 | 0.75 | ATM (0.42) | ATMMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL12292028 | 0.75 | CHRNA7 (0.42) | ATMMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL10349654 | 0.75 | HTR1A (0.55) | ATMMEN1KMT2AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213502-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | Pharmapotheca A, Inc. | 2025-07-03 | — | — | US | disclosed |
| US-12208068-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | Pharmapotheca A Inc. (US) | 2025-01-28 | — | — | US | disclosed |
| CN-117603115-A | Method for preparing cyclic amine from amino alcohol | 中海油天津化工研究设计院有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-20230321010-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | CHEMAPOTHECA, LLC (US) | 2023-10-12 | — | — | US | disclosed |
| US-11717498-B2 | Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms | Pharmapotheca A, Inc. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11123310-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | PHARMAPOTHECA, LLC (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210030699-A1 | Methods of Treatment Using Amphetamine Controlled Release, Prodrug, and Abuse Deterrent Dosage Forms | PHARMAPOTHECA, LLC (US) | 2021-02-04 | — | — | US | disclosed |
| US-20200352883-A1 | METHODS OF TREATMENT USING AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS | CHEMAPOTHECA, LLC (US) | 2020-11-12 | — | — | US | disclosed |
| EP-3478363-A1 | AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE DETERRENT DOSAGE FORMS | Chemapotheca LLC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20180243241-A1 | AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS | CHEMAPOTHECA, LLC | 2018-08-30 | — | — | US | disclosed |
| US-9988349-B2 | Direct stereospecific synthesis of unprotected aziridines from olefins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-05 | — | — | US | disclosed |
| US-9988349-B2 | Direct stereospecific synthesis of unprotected aziridines from olefins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-05 | — | — | US | disclosed |
| WO-2017147375-A1 | AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE DETERRENT DOSAGE FORMS | CHEMAPOTHECA, LLC (US) | 2017-08-31 | — | — | WO | disclosed |
| US-20160340305-A1 | DIRECT STEREOSPECIFIC SYNTHESIS OF UNPROTECTED AZIRIDINES FROM OLEFINS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-24 | — | — | US | disclosed |
| US-20160340305-A1 | DIRECT STEREOSPECIFIC SYNTHESIS OF UNPROTECTED AZIRIDINES FROM OLEFINS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-24 | — | — | US | disclosed |
| EP-0871621-A4 | ASYMMETRIC SYNTHESIS CATALYZED BY TRANSITION METAL COMPLEXES WITH NEW CHIRAL LIGANDS | PENN STATE RES FOUND (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0871621-A1 | ASYMMETRIC SYNTHESIS CATALYZED BY TRANSITION METAL COMPLEXES WITH NEW CHIRAL LIGANDS | THE PENN STATE RESEARCH FOUNDATION (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997013763-A1 | ASYMMETRIC SYNTHESIS CATALYZED BY TRANSITION METAL COMPLEXES WITH NEW CHIRAL LIGANDS | THE PENN STATE RESEARCH FOUNDATION (US) | 1997-04-17 | — | — | WO | disclosed |
| US-4173580-A | Production of β-haloalkylaminosulfonyl halides | BASF AKTIENGESELLSCHAFT (DE) | 1979-11-06 | — | — | US | disclosed |
| US-4014931-A | FROM AZIRIDINE AND SULFURYL HALIDE | BASF AKTIENGESELLSCHAFT (DT) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11123310-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | SLC6A3, CES2, SLC6A2 | ATM 3889/4885MEN1 1784/4885KMT2A 1605/4885 |
| US-11717498-B2 | Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms | SLC6A3, SLC6A2, CES2 | ATM 4009/4885MEN1 2092/4885KMT2A 1539/4885 |
| US-20160340305-A1 | DIRECT STEREOSPECIFIC SYNTHESIS OF UNPROTECTED AZIRIDINES FROM OLEFINS | AAAS, NISCH, HNMT | ATM 2082/4885MEN1 1388/4885KMT2A 808/4885 |
| US-20200352883-A1 | METHODS OF TREATMENT USING AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS | SLC6A3, SLC6A2, CES2 | ATM 4098/4885MEN1 1941/4885KMT2A 1492/4885 |
| US-20230321010-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | SLC6A3, CES2, SLC6A2 | ATM 3782/4885MEN1 1840/4885KMT2A 1784/4885 |
| US-20210030699-A1 | Methods of Treatment Using Amphetamine Controlled Release, Prodrug, and Abuse Deterrent Dosage Forms | SLC6A3, SLC6A2, CES2 | ATM 4009/4885MEN1 2092/4885KMT2A 1539/4885 |
| US-12208068-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | SLC6A3, CES2, SLC6A2 | ATM 3782/4885MEN1 1840/4885KMT2A 1784/4885 |
| US-20250213502-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | SLC6A3, CES2, SLC6A2 | ATM 3889/4885MEN1 1784/4885KMT2A 1605/4885 |
| US-20180243241-A1 | AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS | SLC6A3, CES2, SLC6A2 | ATM 3889/4885MEN1 1784/4885KMT2A 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.